로딩 중…
StockDiggingStockDigging

SAMJIN PHARMACEUTICAL CO.,LTD

005500· KOSPI
₩18,910+0.53%
2026-06-19

Price Chart

SAMJIN PHARMACEUTICAL CO.,LTD-1.72%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap251.88B KRW
Revenue306.35B KRW
Net Income6.60B KRW
Total Assets452.49B KRW
Net Assets277.59B KRW
Employees809
Value
P/E38.14x
P/B0.91x
P/S0.82x
EV/EBITDA122.47x
FCF Yield8.92%
Profitability
ROE2.38%
ROA1.46%
Op. Margin0.97%
Revenue Growth-3.93%
Earnings Growth-62.56%
Financial Health
Debt Ratio63.00%
Total Debt119.00B KRW
FCF22.47B KRW
Cash7.14B KRW
Current Ratio1.28x
Net Debt/EBITDA37.66x
Dividend
Div. Yield4.25%
Div. Growth0.00%
Performance
1Y Return-1.72%
1M Return-12.45%
From 52W High-26.99%
1Y MDD-24.33%
Trading
Volume68,979 shares
Foreign Own.3.46%
Per Share
EPS1,594 KRW
BPS21,931 KRW

Company Info

CEO 최지현, 조규석
Employees 809
Founded 1968
HQ 서울특별시 마포구, KR

Samjin Pharmaceutical, established in 1968, manufactures and sells pharmaceuticals, boasting a diverse portfolio that includes Gabol tablets and Plaless tablets. The company is expanding its business into health functional foods, cosmetics, and medical devices, with a strong focus on developing new drugs for conditions such as cancer and dementia. Following the completion of an EU-GMP-grade injectable line at its Osong raw material synthesis plant in 2022, Samjin Pharmaceutical is boosting production and facility investments for global growth. Samjin Pharmaceutical is headquartered in Mapo-gu, Seoul.